Preventative effects of the partial RANKL peptide MHP1-AcN in a mouse model of imiquimod-induced psoriasis

Ju, Nan; Shimamura, Munehisa; Hayashi, Hiroki; Ikeda, Yuka; Yoshida, Shota; Nakamura, Ayumi; Morishita, Ryuichi; Rakugi, Hiromi; Nakagami, Hironori

doi:10.1038/s41598-019-51681-0

Cited by 12 publications

(9 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4C). We previously showed MHP1-AcN inhibited LPS (TLR4 ligand) and R837 (TLR7 ligand) induced IL-6 in MG6 and RAW 264.7 cells (15,16); in this study, we observed IL-6 was also inhibited in primary macrophages (Supplemental Fig. 3).…”

Section: Mhp1-acn Inhibited Tlr3 and Tlr9 Ligand-induced Il-6 Production In Macrophagessupporting

confidence: 61%

“…Previously, we reported that a partial peptide derived from the receptor activator of the NF-rB ligand (RANKL), microglial healing peptide 1 (MHP1), could inhibit TLR2, TLR4, and TLR7 signaling in the macrophages without osteoclast differentiation (14,15). To increase its stability, we further modified MHP1 with N-terminal acetylation and C-terminal amidation (MHP1-AcN) (16).…”

Section: Introductionmentioning

confidence: 99%

“…To increase its stability, we further modified MHP1 with N-terminal acetylation and C-terminal amidation (MHP1-AcN) (16). MHP1-AcN has shown protective effects against ischemic stroke and an imiquimod-induced psoriasis model in mice (15,17). Although MHP1 was shown to act via RANK, as the knockdown of RANK abolished its inhibitory effect on LPS-induced inflammation (14), it was insufficient to explain its inhibitory effect on TLR2 and TLR7/8 signaling.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Prevention of Acute Lung Injury by a Novel CD14-Inhibitory Receptor Activator of the NF-κB Ligand Peptide in Mice

Hayashi

Shimamura

et al. 2021

ImmunoHorizons

Self Cite

View full text Add to dashboard Cite

Although CD14 has been implicated in the initiation of multiple TLR-mediated inflammatory responses to sepsis and sepsis-related acute lung injury (ALI), an inhibitor of CD14, except for neutralizing Abs, has not been developed. A partial peptide, microglial healing peptide 1 with N-terminal acetylation and C-terminal amidation (MHP1-AcN), derived from the receptor activator of the NF-rB ligand, was recently found to inhibit multiple TLR signaling in the macrophages. Therefore, we hypothesized that the inhibitory effect of MHP1-AcN might be through the inhibition of CD14, a common coreceptor for multiple TLRs. In cultured mouse macrophages, MHP1-AcN was shown to bind to CD14 and compete with LPS for competitive inhibition of CD14, resulting in inhibition of TLR4 signaling, including NF-rB and IFN regulatory factor 3 activation and nuclear translocation. In addition to TLR2, TLR4, and TLR7, MHP1-AcN also inhibited TLR3 signaling and Escherichia coli DNA-induced, CD14-dependent TLR9 signals; however, CpG oligodeoxynucleotide-induced, CD14-independent TLR9 signals were not inhibited in the mouse macrophages. In sepsis-induced ALI mouse model, MHP1-AcN treatment showed the reduction in the expression of IL-6 and CCL2 in both the serum and lung tissues. IL-6 levels in the bronchoalveolar lavage fluid and pathological score were also decreased by MHP1-AcN. Thus, MHP1-AcN, a novel CD14 inhibitor, could be a promising agent for treating sepsis-induced ALI. ImmunoHorizons, 2021, 5: 438-447.

show abstract

Section: Mhp1-acn Inhibited Tlr3 and Tlr9 Ligand-induced Il-6 Production In Macrophagessupporting

confidence: 61%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prevention of Acute Lung Injury by a Novel CD14-Inhibitory Receptor Activator of the NF-κB Ligand Peptide in Mice

Hayashi

Shimamura

et al. 2021

ImmunoHorizons

Self Cite

View full text Add to dashboard Cite

show abstract

“…The results were more than promising. In addition to a reduction in erythema and scales, there were significant decreases in IL-6, IL-23, and IL-17A (55).…”

Section: Discussionmentioning

confidence: 91%

Experimental research in topical psoriasis therapy (Review)

et al. 2021

View full text Add to dashboard Cite

Psoriasis, one of the most prevalent inflammatory diseases in dermatologic pathology, remains a challenge in regards to the therapeutic approach. Topical therapy for psoriasis is a current trending subject as it implies good compliance for the patient, few adverse systemic reactions and a targeted effect. Numerous substances are now being tested, from natural to synthetic compounds and already known substances in improved formulas such as vesicular systems. The aim of this article was to conduct a literature review regarding the topical therapy of psoriasis in animal models, between June, 27, 2019 and July 9, 2020. For this article, the authors conducted extensive research in PubMed with the following keywords: Psoriasis AND (topical OR local) and (therapy OR treatment) AND (mice OR rats). The main new studied substances included lycopene, sodium butyrate, salvianolic acid B, small interfering RNAs (siRNAs) in ionic liquids, albendazole, phosphodiesterase inhibitors, biomimetic reconstituted highdensity lipoprotein nanocarrier gel containing microRNA (miRNA)-210 antisense, thymoquinone in ethosomal vesicle, Sea buckthorn oil (Hippophae rhamnoides), nitidine chloride, Melissa officinalis spp. Altissima extract and [1-(4-chloro-3nitrobenzenesulfonyl)-1H-indol-3-yl]-methanol (CIM). New formulas of already known anti-psoriasis substances such as: Cyclosporine, methotrexate, calcipotriol, tazarotene, protein kinase p38 and integrin α5β1 as a target, are also reviewed. Recent research in topical psoriasis underlines the importance of animal experimental research in dermatology, providing a starting point for developing new therapeutic approaches in one of the most frequently diagnosed chronic dermatologic diseases. Vesicular systems are now providing the best vehicle for topical therapy, thus easing the action of the active substances at their target sites. Contents 1. Introduction 2. Research methods 3. Summary and discussion of the new topical treatment strategies 4. Discussion 5. Conclusions

show abstract

“…Only four of the 100 studies analysed indicated that they followed the ARRIVE guideline. [20][21][22][23] However, irrespective of the in- . 24 The first guideline was published in 2010 25 and from then there have been different updates, the last in 2020.…”

Section: Re Sults and Discussionmentioning

confidence: 99%

Methodological shortcomings in the reports of the imiquimod psoriatic model

Vinardell

2021

Experimental Dermatology

View full text Add to dashboard Cite

Psoriasis is a chronic inflammatory skin disease affecting about 2-3% of the worldwide population with lower prevalence in Asian and some African populations and up to 11% in Caucasian and Scandinavian populations. 1 Psoriasis is a multifactorial disease with different factors such as genetic factors, alterations in the immune system, and environmental conditions among others and characterized by infiltration of immune cells, epidermal hyperproliferation, and abnormal keratinocyte differentiation. 2 There are different types of psoriatic manifestations, the most common form corresponds to plaques, typically has raised red or white scaly skin lesions with a thickened epidermis and covering large areas of the skin. 3 The presence of vascular engorgement and alteration on epidermal cell cycles are characteristics of patients with psoriasis. Such changes may be related to the various inflammatory cytokines released in

show abstract

Preventative effects of the partial RANKL peptide MHP1-AcN in a mouse model of imiquimod-induced psoriasis

Cited by 12 publications

References 35 publications

Prevention of Acute Lung Injury by a Novel CD14-Inhibitory Receptor Activator of the NF-κB Ligand Peptide in Mice

Prevention of Acute Lung Injury by a Novel CD14-Inhibitory Receptor Activator of the NF-κB Ligand Peptide in Mice

Experimental research in topical psoriasis therapy (Review)

Methodological shortcomings in the reports of the imiquimod psoriatic model

Contact Info

Product

Resources

About